GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Coral Laboratories Ltd (BOM:524506) » Definitions » Debt-to-Equity

Coral Laboratories (BOM:524506) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2001. Start your Free Trial

What is Coral Laboratories Debt-to-Equity?

Coral Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.0 Mil. Coral Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was ₹0.0 Mil. Coral Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ₹1,775.0 Mil. Coral Laboratories's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Coral Laboratories's Debt-to-Equity or its related term are showing as below:

BOM:524506' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01   Med: 0.02   Max: 0.05
Current: 0.01

During the past 13 years, the highest Debt-to-Equity Ratio of Coral Laboratories was 0.05. The lowest was 0.01. And the median was 0.02.

BOM:524506's Debt-to-Equity is ranked better than
99.88% of 847 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs BOM:524506: 0.01

Coral Laboratories Debt-to-Equity Historical Data

The historical data trend for Coral Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coral Laboratories Debt-to-Equity Chart

Coral Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.04 - -

Coral Laboratories Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - N/A 0.01 N/A -

Competitive Comparison of Coral Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Coral Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Coral Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Coral Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Coral Laboratories's Debt-to-Equity falls into.



Coral Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Coral Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Coral Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Coral Laboratories  (BOM:524506) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Coral Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Coral Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Coral Laboratories (BOM:524506) Business Description

Traded in Other Exchanges
N/A
Address
Lal Bahadur Shastri Road, No. 3-B, Patanwala Industrial Estate, Opposite Shreyas Cinema, Ghatkopar (West), Mumbai, MH, IND, 400086
Coral Laboratories Ltd is engaged in the pharmaceutical business. The company is involved in the formulation of medicines. The company's dosage form includes tablets, capsules, liquid orals, b-lactam, dry syrup, meter dose inhaler, injectable, drops, sprays, special kits, and others.

Coral Laboratories (BOM:524506) Headlines

No Headlines